Info

MetriGenix develops and delivers solutions that enable the rapid growth of emerging molecular diagnostic assays. These solutions are comprised of validated genomic biomarker panels and genomic test instrumentation to deliver clear diagnostic results for patient care, clinical trials and research applications. Genomic Biomarker Panels: MetriGenix performs translational development to validate and commercialize a portfolio of disease biomarkers for diagnosis, prognosis and surveillance of disease status. MetriGenix,s portfolio comprises product opportunities that are discovered in-house or licensed-in from leading research institutions. Currently the portfolio is focused on select inflammation and autoimmune diseases. Our diagnostic test development program is enabled by assets such as:, Access to a large database of expression profiles across major disease categories, Low-cost, high throughput gene expression profiling systems, Intellectual property rights to molecular biomarkers and methodology, Collaboration with leading medical experts for access to clinical samples and data, execution of clinical validation studies, and early adoption, Expertise in developing clinical diagnostic productsGenomic Test Instrumentation: MetriGenix has developed an automated, patent-protected instrument for highly multiplexed molecular diagnostic assays. Our Flow-Thru-ChipÔ technology is the core of a robust, precise, and fully automated analytical system capable of processing 8 chips in parallel. Benefits for clinical and research applications include:, High content - hundreds of targets per sample, RNA, DNA or protein targets, Fully automated processing of multiple tests in parallel, Short assay time, Strong technical performance (sensitivity, reproducibility), Numerical output of test results, ,Load-lock-and leave, automated operation, Cost effectivenessGene Expression Services: MetriGenix also provides outsourced gene expression services for clients requiring high throughput, low cost screening assays on targeted sets of genes (e.g. 100-400 end-points). Automated sample processing and high throughput analytical platforms are available for projects involving hundreds or more test samples. In December of 2004, MetriGenix acquired Woburn, Massachusetts-based GeneXP Biosciences, Inc., to expand the portfolio of biomarker product opportunities and add capabilities and tools to its product development efforts. The combined company is leveraging low-cost, high-throughput array technologies and other assets to accelerate the validation and commercialization of a selected set of molecular diagnostic products. Dear visitor to our website. We are in the process of updating our website. Please excuse the work in progress nature of this page and the fact that the other content is temporarily unavailable.